Publication | Closed Access

Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: The ANRS VAC14 study

VaccinationCandidate VaccineVaccine DevelopmentRecombinant Hiv-1 Gp160ImmunologyVaccine TestingHivMedicineVaccine ResearchAnrs Vac14 Study